Everest Medicines announces new strategic plans to bring transformation into a fully integrated biopharma company

Everest Medicines, a biopharmaceutical company, has announced its strategic plans for the next two years and beyond, as the company strives to become a fully-integrated biopharmaceutical company with expertise and capabilities spanning the entire biotechnology value chain, including proven self-discovery and in-licensing, clinical development, and established manufacturing and commercialization. Everest's primary focus will be on the company's renal disease and mRNA platform portfolios, both of which contain numerous promising early- and late-stage therapeutic candidates.

"Over the past five years, Everest has had impressive growth, evolving from its successful in-licensing model to developing strong capabilities in both self-discovery and business development, both of which we will continue to leverage as we transition into a fully integrated biopharma company and establish ourselves as an Asia-based industry leader with a global footprint," said Everest Medicines CEO Rogers Yongqing Luo. "In this next stage of corporate growth, we are focusing on developing commercialization capabilities that will enable the successful launch of multiple late-stage assets over the next five years, led by Nefecon."

Nefecon, the company's lead renal portfolio product candidate, is expected to be approved and launched in China in the second half of 2023. China has the highest prevalence of primary glomerular disease in the world, with approximately 5 million patients suffering from IgA nephropathy. EVER-COVID19-M1, a bivalent Covid-19 booster, is the Company's lead mRNA candidate, and it plans to initiate clinical trials and file an Emergency Use Authorization application in China in 2023. Everest has completed industrial-scale technology transfer, advanced its clinically-validated mRNA platform, and successfully completed trial production runs at its commercial-scale manufacturing facility in Jiashan, China, in less than 16 months since its partnership with Providence Therapeutics Holdings Inc.

Everest will continue to leverage the full potential of its mRNA technology platform to drive the development of preventive and therapeutic vaccines against various infectious diseases and cancers, in addition to its Covid-19 programme. In addition to the company’s focus on renal diseases and mRNA platform, it is also pursuing several product candidates in the pipeline with best-in-class potential, including Xerava which is also expected to receive NDA approval in 2023, and etrasimod for the treatment of ulcerative colitis. Everest Medicines is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets.